Co-administration of IWR-1 and doxorubicin in vivo significantly reduced tumor progression, associated with specific downregulation of TCF/LEF transcriptional activity, nuclear β-catenin, and the CSC marker Sox2.701. This evidence concerns the gene HNF4A and neoplasm.